Streptococcus pyogenes, the pathogen of erysipelas, has an antitumor activity.1>2) The culture broth and the cells of the bacterium have used for therapy of malignant tumor patients.3~5)
Yoshida et al. 6 ) isolated the streptococcal acid glycoprotein (SAGP) from the cultured cells of a strain with low virulence, S. pyogenes Su, as a principal substance for the cytotoxicity against tumor cells. In vitro tests7) showed that SAGP was a selective growth inhibitor ofa variety of tumor cells. The growth of sensitive cells such as HeLa and sarcoma 180 was inhibited by very low doses of SAGP, but that of insensitive cells such as QG56and P388 was not affected. Wefound that the in vivo antitumor activity of SAGPresulted from a direct cytotoxic effect against tumor cells, but not from stimulating the immunesystem of host animals.7) In addition, we cloned the SAGP gene in E. coli from the chromosome of S. In this report, we describe the cloning of the 5' flanking region of the SAGPgene, expression of SAGPin E. coli cells, and characterization 743 of the purified recombinant SAGPin comparison with the native SAGPisolated from S.
pyogenes Su cells. Also, the importance of quaternary structure for the antitumor activity of SAGPis discussed.
Materials and Methods
Enzymes and reagents. Restriction enzymes, T4-DNA ligase, bacterial alkaline phosphatase, BAL31 nuclease, and dideoxy DNAsequencing kit were purchased from Takara Shuzo (Kyoto, Japan). Isopropyl-/?-D-thiogalactoside (IPTG) was obtained from Sigma (St. Louis, MO, U.S.A.). 32P-ATP and 35S-CTP were from Amersham Japan (Tokyo, Japan).
Bacterial strains and plasmids. Streptococcus pyogenes Su was used as the source of chromosomal DNA,8) and the native SAGP.7) Escherichia coli JM103 was used for propagation of plasmids, and for expression of the recombinant SAGP. Plasmids pUC18 and pUC19 were purchased from Takara Shuzo. The expression vector pKK223-4 was constructed from pKK223-3 (Pharmacia LKB Biotechnology; Uppsala, Sweden) by removing one of two BamHlsites as reported previously.9) The plasmid ptacSP for expression of SAGPwas described.8) Construction of expression plasmids Figure 2A shows the scheme for construction of plasmids pSP31, ptacSP2, and ptacSP3 for expression of the SAGPgene in E. coli. Plasmid pSP31 was prepared to investigate whether a putative promoter of the SAGPgene derived from S. pyogenes Su would work in E. coli cells.
This plasmid was constructed from pSP3 carrying the 5' flanking region of the SAGP gene, and pSPl containing the SAGPcoding region. Plasmids ptacSP2 and ptacSP3 were constructed to overproduce SAGPin E. coli cells. Figure 2B shows the nucleotide sequences between the ribosome binding site and the ATG Therefore, the 5' flanking region of the SAGP gene did not seem to contain a promoter sequence functional in E. coli.
Purification of the recombinant SAGP The recombinant SAGPwas purified from a 5.5-1 culture of E. coli JM103/ptacSP. Table  I summarizes the results of the purification. Figure 4 shows the SDS-polyacrylamide gel electrophoresis of SAGP fractions from the purification steps. The recombinant SAGPwas recovered in the soluble fraction of the cell lysate. Purification was accomplished by ammonium sulfate precipitation, 2 cycles of ionexchange HPLC, and gel filtration HPLC. The yield of the recombinant SAGPwas 53mg, which was much higher than that from cultured cells ofS. pyogenes Su (35mg from a 120-1  culture7) ). The recombinant SAGPsample had more than 90% purity when measured by densitometry of an SDS-polyacrylamide gel (Fig.  4, lane 6) .
Characteristics of the recombinant SAGP The N-terminal amino acids of the purified recombinant SAGP were Thr-Ala-Gln-ThrPro-Ile-X-Val (X indicates a residue which could not be identified with certainty). The sequence was identical with that of the native SAGP isolated from S. pyogenes Su. The sequence also indicated that the N-terminal methionine was removed in the recombinant E. coli cells.
The recombinant SAGP had an apparent dimer and the native SAGPwas a tetramer. Stability of the native and the recombinant SAGPsamples under various pH conditions, freezing and thawing treatment, and a reductive reagent was assessed using gel filtration HPLC. Whenincubated at various pHs, the native SAGP dissociated into a dimer, as shown in Fig. 6A . Under conditions of pH 9 and higher, both SAGPsamples dissociated into a monomer. Moreover, as presented in Fig. 6B , nearly half of the native SAGPwas dissociated into dimer by five cycles of freezing and thawing, while the recombinant SAGP remained unchanged under the same conditions. Neither SAGPwas affedted by incubation with 5% 2-mercaptoethanol at 30°C for 16hr (data not shown).
Antitumor activity of the recombinant SAGP Growth inhibitory activity of SAGPsamples was tested as described7) against sarcoma 180 tumor cells. The IC50 values of the recombinant and the native SAGP samples were 0.3 /ig/ml and 0.07 /ig/ml, respectively.
Thus the recombinant SAGPwas about a quarter as active as the native SAGP.
Discussion
The reported that the N-terminal methionine of some variants of human growth hormone was removed in E. coli when the adjacent amino acid was either an alanine or a threonine, while no processing was observed whenthe adjacent The molecular mass analysis suggested that the recombinant SAGPwas a dimer, while the native SAGP was a tetramer. The primary structure of SAGP contains two cystein residues, but neither the tetramer nor the dimer forms of SAGPwere changed by incubation with a reductive reagent. In addition, dissociations from the tetramer into a dimer by incubation at various pHs and by freezing and thawing, and from the dimer into monomer by incubation at pH 9 and higher were observed. Therefore, the association between SAGP protomers did not appear to involve intersubunit disulfide bridges, but seemed to be due to noncovalent bonding as found with many oligomeric proteins.16) Dissociation of the tetramer did not produce a trimer, and the 749 bonding that forms the dimer appeared to be more stable than that forming the tetramer.
Based upon these observations, it seems reasonable to presume that two SAGP protomers associate to form a dimer, and the dimers are in turn paired to form a tetramer, like the structure of concanavalin A.17) The dimer, either the recombinant SAGP or the one arising by dissociation of the native SAGP, did not readily reassociate to from a tetramer under the usual conditions where the SAGP samples were kept. This may imply that dissociation from the tetramer into the dimer accompanieda conformational rearrangement into a structure that was not readily reversible.
The antitumor activity of the recombinant SAGPwas about a quarter that of the native SAGP isolated from S. pyogenes Su. Also, we found that the antitumor activity of the native SAGPdecreased when incubated at either pH 8.5 or 4.0, and when freeze-dried after dissolved in a low ion-strength solution (unpublished observation). These results suggested a significant relationship between the activity and the quaternary structure of SAGP.Onthe basis of the observed structural behavior, the quaternary structure of SAGPseems to depend on the environments where the protein is synthesized. Thus, the recombinant E. coli strains and the culture conditions mayhave been responsible for the dimer formation.
